ѧÊõÌÃÊ×Ò³ | ÎÄÏ×ÇóÖúÂÛÎÄ·¶ÎÄ | ÂÛÎÄÌâÄ¿ | ²Î¿¼ÎÄÏ× | ¿ªÌⱨ¸æ | ÂÛÎĸñʽ | ÕªÒªÌá¸Ù | ÂÛÎÄÖÂл | ÂÛÎIJéÖØ | ÂÛÎÄ´ð±ç | ÂÛÎÄ·¢±í | ÆÚ¿¯ÔÓÖ¾ | ÂÛÎÄд×÷ | ÂÛÎÄPPT
ѧÊõÌÃרҵÂÛÎÄѧϰƽ̨Äúµ±Ç°µÄλÖãºÑ§ÊõÌà > ÉúÎïѧÂÛÎÄ > Éñ¾­ÉúÎïѧÂÛÎÄ

°¢¶û´Äº£Ä¬²¡·¢²¡»úÖÆÖÐMMPsµÄ×÷ÓÃ

À´Ô´£ºÖйú±È½ÏҽѧÔÓÖ¾ ×÷ÕߣºÑîÈ÷,ÕÅÕñÇ¿,ËξüÓª,
·¢²¼ÓÚ£º2021-03-01 ¹²9573×Ö

¡¡¡¡Õª    Òª£º¡¡°¢¶û´Äº£Ä¬²¡£¨Alzheimer’s disease£¬AD£©ÊÇÒ»ÖÖ²»¿ÉÄæµÄ½¥½øÐÔ·¢Õ¹µÄÉñ¾­ÍËÐÐÐÔ¼²²¡£¬Æä·¢²¡»úÖƸ´ÔÓ£¬²¡Àí±ä»¯Ö÷ÒªÉæ¼°βµí·ÛÑùµ°°×³Á»ý£¬Tauµ°°×¹ý¶ÈÁ×Ëữ£¬Éñ¾­Ñ×Ö¢ºÍÍ»´¥Òì³£µÈ¡£ÔÚ°¢¶û´Äº£Ä¬²¡·¢²¡¹ý³ÌÖУ¬»ùÖʽðÊôµ°°×ø¼Ò×å(matrix metalloproteinases£¬MMPs)¿Éͨ¹ýÓ°Ïìβµí·ÛÑùµ°°×µÄ´úл¡¢²ÎÓëTauµÍ¾ÛÎïµÄÐγɡ¢ÆÆ»µÄÔ²¿ÆÁÕϹ¦ÄÜ¡¢´Ù½øÉñ¾­Ñ×Ö¢¡¢ÒÔ¼°Ó°ÏìÍ»´¥¿ÉËÜÐԵȸı䰢¶û´Äº£Ä¬²¡µÄ²¡Àí½ø³Ì¡£Í¨¹ý¶Ô½üÄêÀ´»ùÖʽðÊôµ°°×øÓë°¢¶û´Äº£Ä¬²¡µÄÑо¿×÷Ò»×ÛÊö£¬ÒÔÆÚΪ»ùÖʽðÊôµ°°×ø×÷Ϊ°¢¶û´Äº£Ä¬²¡Ç±ÔÚÖÎÁưбêÌṩÀíÂÛÒÀ¾Ý¡£

¡¡¡¡¹Ø¼ü´Ê£º¡¡°¢¶û´Äº£Ä¬²¡; »ùÖʽðÊôµ°°×ø; ѪÄÔÆÁÕÏ;

¡¡¡¡Abstract£º¡¡Alzheimer’s disease is an irreversible and progressive neurodegenerative disease. Its pathogenesis is complicated, and its pathological changes mainly involve β-amyloid protein deposition, Tau protein hyperphosphorylation, neuroinflammation and synaptic abnormalities. The matrix metalloproteinase family can alter the pathological process of Alzheimer’s disease by influencing β-amyloid metabolism, participating in the formation of Tau oligomers, disrupting brain barrier function, promoting neuroinflammation, and influencing synaptic plasticity. To provide a theoretical basis for matrix metalloproteinases as potential therapeutic targets for Alzheimer’s disease, we reviewed the existing research on matrix metalloproteinases and Alzheimer’s disease.

¡¡¡¡Keyword£º¡¡Alzheimer's disease; matrix metalloproteinase; blood brain barrier;

¡¡¡¡°¢¶û´Äº£Ä¬²¡£¨Alzheimer’s disease, AD£©ÊÇÒÔÈÏÖªÐÐΪ¶ñ»¯ºÍ¼ÇÒäÁ¦¼õÍËΪÁÙ´²±íÏÖµÄÉñ¾­ÍËÐÐÐÔ¼²²¡¡£ADµÄ֢״ʼÓÚ¶ÌÆÚµÄÇá¶È¼ÇÒäȱÏÝ£¬Ëæʱ¼ä¶ñ»¯Öð½¥µ¼ÖÂÑÏÖصļÇÒäɥʧ£¬ÇéÐ÷±ä»¯£¬½¹ÂÇ£¬ÒÖÓô£¬¼¤¶¯£¬¿Õ¼ä¶¨ÏòÕÏ°­£¬Ô˶¯ÕÏ°­£¬×îºó·¢Õ¹Îª³Õ´ô[1]¡£ADÄÔ²¿ÌØÕ÷ΪÓÉÓÚÉñ¾­ÔªÏ¸°ûËÀÍöºÍÊ÷Í»¼õÉÙÒýÆðµÄ´óÄÔƤÖʺÍijЩƤÖÊÏÂÇøÓòµÄ½øÐÐÐÔήËõ¡£Ñо¿±íÃ÷£¬βµí·ÛÑùµ°°×£¨β-amyloid protein, A⣩³Á»ý¡¢Tauµ°°×¹ý¶ÈÁ×Ëữ¡¢Éñ¾­Ñ×Ö¢¡¢Í»´¥Òì³£µÈ¶¼»áµ¼ÖÂADµÄÉñ¾­ÍËÐÐÐÔ±ä[2]¡£¾¡¹ÜADÖÐDZÔÚµÄÖ²¡»úÖƶàÖÖ¶àÑù£¬µ«»ùÖʽðÊôµ°°×ø¼Ò×å(matrix metalloproteinases, MMPs)ÓëADµÄÉñ¾­ÍËÐÐÐÔ±äÃÜÇÐÏà¹Ø¡£MMPsÔÚ´óÄÔÖпɵ÷½ÚÉú³¤Òò×Ó¼¤»î£¬Ã¸Ô­ÁѽâºÍϸ°ûÍâ»ùÖʵÄÖØËÜ£¬¶Ô×éÖ¯Ðγɡ¢Éñ¾­ÔªÍøÂçÐÞ¸´ºÍѪÄÔÆÁÕÏÍêÕûÐÔÖÁ¹ØÖØÒª[3]¡£ÔÚ½¡¿µÈ˵ĴóÄÔÖз¢ÏÖMMPsˮƽ·Ç³£µÍ¡£È»¶ø£¬ÔÚÉñ¾­ÍËÐÐÐÔ¼²²¡ÈçADÖÐMMPsµÄˮƽÉϵ÷£¬ÏÖ¾ÍMMPsÓëAD²¡Àí½ø³ÌµÄ¹Øϵ×÷Ò»×ÛÊö¡£
 

°¢¶û´Äº£Ä¬²¡·¢²¡»úÖÆÖÐMMPsµÄ×÷ÓÃ
 

¡¡¡¡1 ¡¢MMPs¸ÅÊö

¡¡¡¡MMPsÊǶ๦ÄܵÄÄÚëÄø£¬ÔÚ×éÖ¯ÐÎ̬·¢Éú¡¢Ï¸°ûǨÒƺÍѪ¹ÜÉú³ÉÖÐÆð×÷Óã¬Ò²²ÎÓëÉË¿ÚÓúºÏ£¬Ñ×Ö¢·´Ó¦ºÍ°©Ö¢µÈ¹ý³Ì¡£¸ù¾Ýµ°°×½á¹¹ÓòºÍ×÷Óõ×ÎïµÄ²»Í¬£¬MMPs¿É·ÖΪÎåÀࣺÃ÷½ºÃ¸£¨MMP -2ºÍMMP -9£©¡¢ÈÜѪËØ£¨MMP-3ºÍ-10£©¡¢½ºÔ­Ã¸£¨MMP-1£¬-8ºÍ-13£©¡¢Ä¤ÐÍMMP£¨MMP-14£¬-15£¬-16£¬-17µÈ£©ºÍÆäËûMMPs[4]¡£Õý³£Çé¿öÏ£¬MMPsµÄ±í´ïˮƽ½ÏµÍ£¬ËüÃÇͨ³£ÒÔÎÞ»îÐÔøԭµÄÐÎʽ·ÖÃÚ£¬ÐèÒªÏÈͨ¹ýµ°°×Ë®½âÈ¥³ýÇ°ëĽṹÓò²Å¾ßÓÐø»îÐÔ£¬²¢Êܵ½MMPsµÄÌض¨×éÖ¯ÒÖÖƼÁµÄÑϸñµ÷¿Ø[4]¡£

¡¡¡¡ÔÚÉñ¾­ÍËÐÐÐÔ¼²²¡ÈçADÖУ¬MMPs±¸ÊܹØ×¢£¬ÒòΪ:¢ÙMMPs¹ã·º±í´ïÓÚËùÓÐÀàÐ͵ÄÖÐÊàÉñ¾­ÏµÍ³Ï¸°ûÖУ»¢ÚMMPsͨ¹ýÑ×ÐÔ½éÖÊÈçϸ°ûÒò×Ó¡¢Ç÷»¯Òò×ӺͽôÃÜÁ¬½Óµ°°×µÄÁѽâÀ´µ÷½ÚÂýÐÔÉñ¾­Ñ×Ö¢¹ý³Ì£»¢ÛMMPs¿ØÖƲÎÓëϸ°û¼äÏ໥×÷ÓõÄϸ°ûÍâ»ùÖʺͿçĤµ°°×µÄ¼Ó¹¤£»¢ÜMMPs¿ÉÒÔÆô¶¯»ò³ÉΪµ°°×Ë®½â¼¶Áª·´Ó¦µÄÒ»²¿·Ö£¬´Ó¶øÔÚÖÚ¶àøºÍµ×ÎïÖ®¼äµÄÏ໥×÷ÓÃÖзŴóϸ°û·´Ó¦[5]¡£

¡¡¡¡2¡¢ MMPsÓëAβµÄ´úл

¡¡¡¡AβÊÇÓɵí·ÛÑùµ°°×Ç°Ìåµ°°×£¨amyloid precursor protein, APP£©ÔÚøµÄ×÷ÓÃϾ­Ë®½âÁѽâ²úÉú¡£APP±»α-·ÖÃÚøʶ±ðÁѽâµÄ¹ý³Ì³ÆΪ·Çµí·ÛÑù´úл£¬α-·ÖÃÚøÁѽâAPPÉú³ÉsAPPαºÍ¾ßÓÐ83¸ö°±»ùËáµÄC¶ËƬ¶Î£¨C83£©£¬sAPPα¾ßÓÐÉñ¾­±£»¤ºÍ´Ù½ø¼ÇÒäÔöÇ¿µÄ¹¦ÄÜ¡£È»¶ø£¬Ëæ×ÅÄêÁäµÄÔö³¤£¬α-·ÖÃÚø»áÖð½¥±äµÃЧÂʵÍÏ¡£Õâ»áµ¼ÖÂAPP±»·ÇÌØÒìÐÔµ°°×ø£¨ÀýÈçβ-·ÖÃÚøºÍγ-·ÖÃÚø£©½Ø¶Ï£¬´Ó¶ø´Ù½øAPPµÄµí·ÛÑùµ°°×Áѽâ;¾¶[6]¡£APPµÄµí·ÛÑùÁѽâ;¾¶¿É²úÉú¾ßÓÐϸ°û¶¾ÐÔµÄA⣬ËüÃÇÊǵ¼ÖÂADÖÐÉñ¾­¶¾ÐÔµÄÖØÒªÒòËØ¡£

¡¡¡¡AβµÄ´úлÓëתÔËʧºâÊÇADµÄÒý·¢ÒòËØ£¬´óÄÔÇå³ýAβÖ÷Ҫͨ¹ýøµÄ½µ½â¡¢ÑªÄÔÆÁÕÏתÔË¡¢Ï¸°ûÍÌÊɺÍÄÔĤÁÜ°ÍϵͳÒýÁ÷µÈ·½Ê½½øÐÐ[7]¡£MMPs¼Ò×åµÄ²¿·Ö³ÉÔ±¾ßÓнµ½âAβµÄ×÷Óá£MT1-MMPÊÇÒ»ÖÖĤÐÍMMP£¬¿ÉÒÔ´¦Àí¶àÖÖϸ°ûÖÜΧµ°°×£¬»¹¿ÉÒÔ´ß»¯Ã¸Ô­proMMP-2£¬Ê¹Æäת»¯Îª¾ßÓлîÐÔµÄMMP-2ÐÎʽ¡£MT1-MMP¿ÉÒÔ½µ½âCOS-1ϸ°ûÖбí´ïµÄÌìÈ»¿çĤÐÎʽµÄA⣬Ҳ¿ÉÒÔÔÚÌåÍâ½µ½âAβµÄ¿ÉÈÜÐÔºÍÔ­ÏËάÐÎʽ[8]¡£MT1-MMP½éµ¼µÄAPP´¦ÀíÊÍ·ÅÁË¿ÉÈÜÐÔAPPƬ¶Î£¬´Ë¹ý³Ì²¿·ÖÐèÒª¼¤»îÄÚÔ´ÐÔMMP-2[9]¡£´ËÍ⣬MMP-2ºÍMMP-9Ò²²ÎÓëAβµÄ´úл¡£APP/PS1ת»ùÒòСÊóµÄAβ°ß¿éÖÜΧµÄÐÇÐνºÖÊϸ°ûÖÐMMP-2ºÍMMP-9µÄˮƽÉý¸ß£¬MMP-9¾ßÓÐÀàËÆ·ÖÃÚøµÄ»îÐÔ£¬²¢ÔÚ¶à¸öλµãÇиîAPP£¬´Ó¶ø´Ù½øÁËAPPµÄ·Çµí·ÛÑùÉú³É¹ý³ÌºÍAβµÄÇå³ý¡£ÐÇÐνºÖÊϸ°ûÌõ¼þÅàÑø»ùÄܹ»½µ½âA⣬²¿·ÖÔ­ÒòÊÇͨ¹ýÅàÑø»ùÖеÄMMP-9·¢»Ó¸Ã×÷ÓÃ[10]¡£´ó¶àÊýAβ½µ½âø£¬ÀýÈçÄÚƤËØת»¯Ã¸£¬ÒȵºËؽµ½âøºÍÖÐÐÔÈÜøÔںܴó³Ì¶ÈÉϱíÏÖ³ö¶Ô¿ÉÈÜÐÔAβµÄ½µ½â£¬¶ø²»ÊÇÔ­ÏËάAβ¡£µ«ÊÇ£¬MMP-9Äܹ»ÌåÍâ½µ½âÔ­ÏËάAβ¡£²»Í¬ÄÔϸ°û²úÉúµÄMMP-2 ºÍMMP-9ÒÔ¼°Á½ÖÖøµÄ°ûÍⶨλ¶¼Ç¿µ÷ÁËËüÃÇ×÷ΪÌåÄÚ²ÎÓëÇå³ýAβ³Á»ýÎïµÄÏà¹Ø²ÎÓëÕßµÄDZÁ¦£¬ÕâÒ»·½·¨ÒÑÔÚÌåÄڵõ½ÑéÖ¤£¬ÔÚÌåÄÚ×¢Èë¶àÖÖMMPÒÖÖƼÁ£¬µ¼ÖÂAβˮƽÉý¸ß[11]¡£³ýÁËMMP-2ºÍMMP-9£¬ÆäËûMMPÒ²»á½µ½âAβ¡£ÀýÈ磬½ðÊôÅäÌåÂÈà­Åµ´¼Í¨¹ýMMP-3»î»¯µÄ»úÖƴ̼¤Ï¸°ûÅàÑøϵͳÖеÄAβ½µ½â[12]¡£MMP-7ÁѽâAβ40ºÍAβ42£¬ÕâÒ»¹ý³ÌÊÜAβÓëCu2+½áºÏµÄÒÖÖÆ[13]¡£

¡¡¡¡¾¡¹ÜÔ­ÔòÉÏÈÏΪMMPs¶ÔAβµÄ½µ½â×÷ÓÃÊÇÓÐÒæµÄ£¬µ«MMPsÊǶ๦ÄÜø£¬Æä×÷Óò»½öÈ¡¾öÓÚ±í´ïËüÃǵÄϸ°ûÀàÐÍ£¬¶øÇÒÈ¡¾öÓÚËùÉæ¼°µÄµ×Îï»ò²¡Àí±³¾°¡£´óÄÔÖгÁ»ýµÄAβ³ýÁ˸÷ÖÖøµÄ½µ½âÖ®Í⣬¿çѪÄÔÆÁÕÏÔËÊäÒ²ÊÇÒ»ÖÖÖØÒªµÄÇå³ý·½Ê½¡£¾Ý±¨µÀ£¬ÔÚAD»¼ÕßÖУ¬Õû¸öѪÄÔÆÁÕϵÄAβÇå³ýÂʽµµÍÁËÔ¼30£¥[14]¡£µÍÃܶÈÖ¬µ°°×Ïà¹ØÊÜÌåµ°°×-1£¨low-density lipoprotein receptor-related protein-1£¬LRP-1£©Î»ÓÚѪÄÔÆÁÕÏÉÏ£¬ÊÇÓÐÖúÓÚÇå³ý´óÄÔÖÐAβµÄÊÜÌ壬MMP-9ÔÚLRP-1ÉÏÓÐÒ»¸ö½áºÏλµã£¬²¢ÓëLRP-1µÄµ°°×Ë®½âÍÑÂäÓйء£MMP-9ÒÖÖƼÁSB-3CTµÄµ÷½Ú´Ù½øÁ˵¥ÌåAβÔÚÌåÍâѪÄÔÆÁÕÏÄ£ÐÍÖдӻùµ×Íâ²àÏò¶¥¶ËµÄתÔË£¬ÕâºÜ¿ÉÄÜÊÇÖ¬µ°°×ÊÜÌåÍÑÂä¼õÉٵĽá¹û[15]¡£

¡¡¡¡3 ¡¢MMPsÓë´óÄÔÆÁÕϹ¦ÄܵÄÆÆ»µ

¡¡¡¡ÑªÄÔÆÁÕϺÍѪҺ-ÄÔ¼¹ÒºÆÁÕÏÊÇÄÔ²¿µÄÖ÷ÒªÆÁÕϽṹ£¬Ö÷Ҫά³Ö´óÄÔ΢»·¾³µÄÎȶ¨¡£ÑªÄÔÆÁÕϵÄÆÁÕÏÌØÐÔÖ÷Ҫȡ¾öÓÚÄÔëϸѪ¹ÜÄÚƤ£¬ÄÚƤϸ°ûÖ®¼äµÄ½ôÃÜÁ¬½ÓÒÔ¼°»ùµ×Ĥ¡£ÄÔëϸѪ¹ÜÄÚƤϸ°ûÊÇСµÄÇ×Ë®»¯ºÏÎïÆÁÕÏ¡£½ôÃÜÁ¬½Ó´¦ÃÜ·âÁËÏàÁÚÄÚƤϸ°ûÖ®¼äµÄ·ì϶£¬´Ó¶ø·ÀÖ¹ÁËÈÜÖʺÍϸ°ûµÄÅÔϸ°ûͨ¹ý¡£»ùµ×ĤÄܹ»½«ÄÚƤϸ°ûÓëÖÜϸ°ûºÍÐÇÐνºÖÊϸ°ûÁ¬½ÓÆðÀ´£¬ÐγÉÉñ¾­Ñª¹Üµ¥Î»[16]¡£ÑªÒº-ÄÔ¼¹ÒºÆÁÕÏÓɵ¥²ãÂöÂç´ÔÉÏƤϸ°û×é³É£¬Í¨¹ý²úÉúÄÔ¼¹Òº²¢ÏÞÖƲ»Á¼·Ö×ӺͲ¡Ô­Ìå½øÈë´óÄÔÀ´Î¬³ÖÖÐÊàÉñ¾­ÏµÍ³ÎÈ̬¡£

¡¡¡¡ÑªÄÔÆÁÕϺÍѪҺ-ÄÔ¼¹ÒºÆÁÕϹ¦ÄÜÕÏ°­ÓëADÃÜÇÐÏà¹Ø¡£Ñо¿ÏÔʾ£¬ÓëÀÏÄêÈÏÖª½¡¿µ»¼ÕßÏà±È£¬Çá¶ÈÈÏÖªÕÏ°­»¼ÕßµÄѪÄÔÆÁÕÏͨ͸ÐÔÃ÷ÏÔÔö¼Ó[17]¡£ÑªÄÔÆÁÕÏͨ͸ÐԸı䵼ÖÂÓж¾ÎïÖÊ´ÓѪҺÖнøÈëÖÐÊàÉñ¾­ÏµÍ³£¬ÒýÆð΢»·¾³ÎÉÂÒ£¬ËðÉËÉñ¾­Ôª¡£ÔÚѪÄÔÆÁÕÏ·Ö½âµÄÇé¿öÏ£¬Aβ´ÓÖÐÊàÉñ¾­ÏµÍ³µÄÇå³ýÂʽµµÍ[14]¡£ÄÚƤϸ°û£¬½ôÃÜÁ¬½ÓºÍ»ùµ×Ĥ¶ÔÓÚÊʵ±µÄÆÁÕϹ¦ÄÜÖÁ¹ØÖØÒª£¬ÑªÄÔÆÁÕϵÄÍêÕûÐÔÊÜÈý¸ö½ôÃÜÁ¬½Óµ°°×¼Ò×åµÄµ÷½Ú£ºclaudins£¬occludinsºÍzonula occludens¡£µ±ÄÚƤϸ°ûÖнôÃÜÁ¬½Óµ°°×µÄ±í´ï½µµÍʱ£¬»áÔö¼ÓѪÄÔÆÁÕÏͨ͸ÐÔ¡£ÄÚƤϸ°ûºÍÐÇÐνºÖÊϸ°û±©Â¶ÓÚAβ1-42µÄ¹²ÅàÑøÑо¿±íÃ÷£¬ÐÇÐνºÖÊϸ°ûÓÕµ¼µÄѪÄÔÆÁÕÏ¿ª·ÅÓëMMP-9µÄ¼¤»îºÍclaudin-5¼õÉÙÓйأ¬claudin-5ÊÇMMP-9µÄµ×ÎÓÐÖúÓÚά³ÖѪÄÔÆÁÕϵŦÄÜ[18]¡£µ±´óÊóÄÔ΢Ѫ¹Ü±©Â¶ÓÚŨ¶È²»¶ÏÔö¼ÓµÄAβ1-40ʱ£¬claudin-1ºÍclaudin-5±í´ïÏÔ׎µµÍ£¬Í¬Ê±°éËæ×ÅMMP-2ºÍMMP-9±í´ïÉý¸ß[19]¡£MMP-2¡¢MMP -9×÷ΪMMPs¼Ò×åµÄÁ½¸ö³ÉÔ±£¬ÔÚ²¡ÀíÌõ¼þϲ»½ö¿ÉÒÔ½µ½â½ôÃÜÁ¬½Óµ°°×£¬¶øÇÒ¿ÉÒÔ½µ½â»ùµ×Ĥ£¬´Ó¶øµ¼ÖÂBBB½á¹¹µÄÆÆ»µ¡£

¡¡¡¡ADÓëÂöÂç´ÔÐÎ̬ºÍ¹¦ÄܵĶàÖֱ仯Óйأ¬ÆäÖÐ×îÍ»³öµÄÊÇÄÔ¼¹ÒºÉú³É¼õÉÙ£¬´úл»îÐԱ仯ºÍ¶¾ËØÇå³ý¡£ÒÖÖÆMMPs»îÐÔ¿É×èÖ¹Aβ1-42µÍ¾ÛÎïÓÕµ¼µÄѪҺ-ÄÔ¼¹ÒºÆÁÕÏÆÆ»µ¡£¹ãÆ×MMPsÒÖÖƼÁGM6001·ÀÖ¹ÁËAβ1-42¹Ñ¾ÛÎï×¢Éä¶ÔѪҺ-ÄÔ¼¹ÒºÆÁÕϵÄÓк¦Ó°Ï죬±íÃ÷MMPs²ÎÓëÁËAβ1-42¹Ñ¾ÛÎïÓÕµ¼µÄѪҺ-ÄÔ¼¹ÒºÆÁÕÏ·Ö½â[20]¡£Ò»ÏîÕë¶ÔСÊó¼¹ËèËðÉËÄ£Ð͵Ä×îÐÂÑо¿±íÃ÷£¬È±·¦MMP-3µÄСÊóÏÔʾ³ö¶ÔѪҺ-ÄÔ¼¹ÒºÆÁÕϵÄÆÆ»µ¼õÉÙ¡£ÏòMMP-3ȱÏݵÄСÊóÄÔÊÒÄÚ×¢ÉäÁËAβ1-42¹Ñ¾ÛÎ²¢·¢ÏÖMMP-3µÄȱʧǿÁÒ½µµÍÁËAβ1-42¹Ñ¾ÛÎïÓÕµ¼µÄѪҺ-ÄÔ¼¹ÒºÆÁÕÏÉø©¡£´ËÍ⣬ÄÔÊÒÄÚ×¢ÉäAβ1-42¹Ñ¾ÛÎïºó£¬ÂöÂç´ÔÖеÄMMP-8£¬MMP-9ºÍMMP-13 mRNAˮƽÉý¸ß£¬Òò´ËÕâЩMMPsÒ²¿ÉÄÜÔÚѪҺ-ÄÔ¼¹ÒºÆÁÕÏÍêÕûÐÔɥʧÖÐÆð×÷ÓÃ[21]¡£

¡¡¡¡4¡¢ MMPsÓëÉñ¾­Ñ×Ö¢

¡¡¡¡Éñ¾­Ñ×Ö¢ÊÇÖ¸·¢ÉúÔÚÖÐÊàÉñ¾­ÏµÍ³µÄÑ×Ö¢·´Ó¦£¬Í¨³£ÊÇÉñ¾­×éÖ¯×÷Ϊ¶ÔÓк¦´Ì¼¤µÄÃâÒßÓ¦´ð¶øÒý·¢µÄ£¬µ±Ñ×Ö¢·´Ó¦¹ý¶È»îԾʱ»áµ¼Ö¶àÖÖÄÔ²¿¼²²¡¡£½ºÖÊϸ°ûÊÇÖÐÊàÉñ¾­ÏµÍ³Ñ×Ö¢·´Ó¦ÖеÄÖ÷Ҫϸ°ûÀàÐÍ¡£µ±±»Ó¦¼¤´Ì¼¤¼¤»îʱ£¬Ï¸°û»áͨ¹ý¸Ä±äÐÎ̬ΧÈƲ¡±ä²¿Î»£¬²¢Í¨¹ýÍÌÊÉÇå³ýϸ°ûËéƬÀ´ÏÞÖÆËðÉË¡£ÓëÄÔÄÚ¶¯Ì¬Æ½ºâɥʧ»ò×éÖ¯¸Ä±äÏà¹ØµÄ¼²²¡»áÓÕ·¢¼¸ÖÖ¶¯Ì¬µÄС½ºÖÊϸ°û¹ý³Ì£¬°üÀ¨Ï¸°ûÐÎ̬£¬±íÃæ±íÐÍ£¬·ÖÃÚ½éÖʺÍÔöÖ³·´Ó¦µÄ¸Ä±ä£¬³ÆΪ“¼¤»î״̬”[22]¡£

¡¡¡¡AD¼²²¡¹ý³ÌÖаéËæ×ÅÂýÐÔ³ÖÐøÐÔÉñ¾­Ñ×Ö¢·´Ó¦£¬Ð¡½ºÖÊϸ°û»î»¯²¢ÊÍ·Åϸ°ûÒò×Ó£¬¿É´Ù½øAβµÄÎüÊÕºÍÇå³ý¡£µ«ËüµÄ³¤ÆÚ¼¤»î»áÒýÆðÉñ¾­¶¾ÐÔºÍÉñ¾­±äÐÔµÄÂýÐÔÑ×֢״̬£¬´Ó¶ø´Ù½øADµÄ²¡Àí½ø³Ì[23]¡£MMPsÊÇÖØÒªµÄÑ×Ö¢³É·Ö£¬¿Éͨ¹ý¶àÖÖ»úÖÆ´Ù½øÉñ¾­Ñ×Ö¢·´Ó¦¡£Ê×ÏÈ£¬MMPs¼¤»îÉñ¾­Ñ×֢;¾¶£¬ÕâÊÇͨ¹ý¼¤»î×÷ÓÃÓÚÐźŷÖ×ÓµÄø¼ä½ÓÍê³ÉµÄ¡£ÀýÈ磬MT4-MMP¾ßÓÐTNF-αת»¯Ã¸»îÐÔ£¬Í¨¹ý¸Ãø¿É½«¿çĤTNF-αµ°°×Ë®½âת»¯Îª¿ÉÈÜÐԵĻîÐÔTNF-α[24]¡£Æä´Î£¬MMPs±¾Éí¾ßÓÐÉñ¾­Ñ×Ö¢ÐźŷÖ×ÓµÄ×÷Óá£LPS»òÕßµòÍöÐźŴ̼¤Éñ¾­Ôªºó£¬¾ßÓлîÐÔµÄMMP-3±»·ÖÃÚµ½¼äÖÊÖУ¬´Ó¶ø´¥·¢Ð¡½ºÖÊϸ°û¼¤»îÒÔ¼°´ÙÑ×ϸ°ûÒò×ӵIJúÉúºÍ·ÖÃÚ[25]¡£µÚÈý£¬MMPsͨ¹ýÍÑÂäÈçFasÅäÌåÖ®ÀàµÄËÀÍö·Ö×Ó£¬Ó°Ïìγ£­°±»ù¶¡ËáºÍ¸Ê°±Ëáˮƽ£¬´Ó¶ø´Ù½øÉñ¾­Ñ×Ö¢½éµ¼µÄÉñ¾­¶¾ÐÔ[26]¡£×îºó£¬Éñ¾­Ñ×Ö¢ÓÕµ¼µÄMMPsͨ¹ýµ°°×Ë®½âÄÔѪ¹Ü»ùµ×ĤºÍ½ôÃÜÁ¬½Óµ°°×£¬µ¼ÖÂÆÁÕϹ¦ÄÜÆÆ»µ[27]¡£ÔÚAD·¢²¡¹ý³ÌÖУ¬ÍâÖÜÃâÒßϸ°ûÈçÁÜ°Íϸ°û¡¢µ¥ºËϸ°ûºÍÊÈÖÐÐÔÁ£Ï¸°û£¬¿ÉÒÔ´©¹ýѪÄÔÆÁÕϲ¢ÉøÈë´óÄÔ[4]¡£Aβ25-35¿ÉÒÔ¼¤»îÈëÇÖµÄÖÐÐÔÁ£Ï¸°û£¬ÕâÊÇ×î·á¸»µÄÃâÒßϸ°û£¬¿ÉÒÔÉø͸µ½´óÄÔÖУ¬²¢´Ì¼¤proMMP-9µÄÊÍ·Å[28]¡£

¡¡¡¡5¡¢ MMPsÓëTauµ°°×

¡¡¡¡Tauµ°°×ÊÇÒ»ÖÖ΢¹ÜÏà¹Øµ°°×£¬Ö÷Òª²ÎÓëά³ÖÉñ¾­ÔªÏ¸°û΢½á¹¹¡£Tauµ°°×Ê×ÏÈ×÷Ϊ΢¹ÜÎȶ¨¼Á·¢»Ó×÷Óã¬ÒÔÆäÌìÈ»¹¹Ïó½áºÏ΢¹Ü²¢´Ù½ø¾ÛºÏ£¬µ«ËüÊÇÒ»ÖÖÁ×µ°°×£¬ÆäÉúÎïѧ»îÐÔÊÜÆäÁ×Ëữ״̬µÄµ÷½Ú£¬Ò»µ©Á×Ëữ¹ý¸ß£¬Tauµ°°×¾Í»á¸Ä±äÆä¹¹Ïó²¢Óë΢¹Ü·ÖÀ룬´Ó¶øʹËüÃDz»Îȶ¨¡£Tauµ°°×ÔÚÖáÍ»Öк¬Á¿¸üΪ·á¸»£¬µ«ÔÚ²¡ÀíÌõ¼þÏ£¬Ëü»áÔÚϸ°ûÌåÖз¢Éú¾ÖÓò»¯ºÍ»ýÀÛ£¬²¢ÔÚÄÇÀïÐγɾۼ¯Ìå[29]¡£ÔÚÉúÀíÌõ¼þÏ£¬Tauµ°°×ÊÇ¿ÉÈܵģ¬¾ßÓÐÓÐÏ޵Ķþ¼¶½á¹¹£¬µ«ÔÚ²¡ÀíÌõ¼þÏ£¬Tauµ°°×´Ó΢¹Ü½âÀë²¢×ÔÎҵ޺ϣ¬ÐγÉÔ­ÏËά¹Ñ¾ÛÌ壬Æä¹Ñ¾ÛÌå¾ßÓÐÉñ¾­¶¾ÐÔ, ¶ÔÉñ¾­Ï¸°û¿ìËÙÖáÍ»ÔËÊä²úÉúÓ°Ïì[30]¡£

¡¡¡¡ÔÚADÖУ¬ÌìȻչ¿ªµÄTau±äµÃ¹ý¶ÈÁ×Ëữ£¬²¢ÇÒÓÉÓÚʧȥ¶Ô΢¹ÜµÄÇ׺ÍÁ¦¶øÇ÷ÓÚ¾Û¼¯£¬×îÖÕÐγÉÉñ¾­ÔªÏËά²ø½á£¨Neuro fibrillary tangles, NFT£©¡£NFTËðº¦ÖáÍ»ÔËÊ䣬µ¼ÖÂÍ»´¥É¥Ê§£¬Ï¸°û¹Ç¼ÜºÍÏßÁ£Ì幦ÄÜÕÏ°­ÒÔ¼°¼ÇÒäɥʧ[31]¡£ADµÄ×éÖ¯²¡ÀíѧÌØÕ÷Ö®Ò»ÊÇ´æÔÚTauµ°°×¹Ñ¾ÛÌ壬¶îҶƤÖÊÖпÅÁ£×´Tauµ°°×¹Ñ¾ÛÌåˮƽµÄÉý¸ß¿ÉÄÜÊÇADµÄÔçÆÚÕ÷Õ×[32]¡£Tauµ°°×¹Ñ¾ÛÌå¿Éͨ¹ý½µµÍÍ»´¥Ð¡ÅÝÏà¹Øµ°°×Í»´¥ËصÄˮƽÀ´Ëðº¦Í»´¥£¬²¢Í¨¹ý½µµÍÑÌõ£°·ÏÙàÑßʶþºËÜÕËá-·ºõ«Ñõ»¯»¹Ô­Ã¸ºÍµç×ÓתÔËÁ´¸´ºÏÎïIµÄˮƽÀ´ÆÆ»µÏßÁ£Ìå[33]¡£MMP-3ºÍMMP-9¶¼¿ÉÒÔÔÚÌض¨²¿Î»ÇиîTauµ°°×¡£ËäÈ»MMP-3ÏÞÖƵĵ°°×Ë®½â×÷ÓÃÔڹ㷺Ñо¿µÄŨ¶È·¶Î§ÄÚ²»»áÔö¼ÓTauµ°°×¾Û¼¯£¬µ«MMP-9È´µ¼ÖÂTauµ°°×¹Ñ¾ÛÌåÐγÉÔö¼Ó¡£Òò´Ë£¬MMP-9¿ÉÒÔÊÍ·ÅTauµ°°×µÄÖظ´½á¹¹Óò£¬´Ó¶ø´Ù½ø¹Ñ¾ÛÌåµÄÐγÉ[34]¡£

¡¡¡¡6¡¢ MMPsÓëÍ»´¥¿ÉËÜÐÔ

¡¡¡¡Í»´¥ÊÇ´óÄÔÖд洢¼ÇÒäºÍ´«µÝÐÅÏ¢µÄ»ù±¾µ¥Î»£¬ÓÉÍ»´¥Ç°ºÍÍ»´¥ºóÇøÊÒ×é³É£¬ÆäÔÊÐíÉñ¾­Ôª½«µç»ò»¯Ñ§ÐźŴ«µÝµ½ÁíÒ»¸öÉñ¾­ÔªÏ¸°û£¬²¢ÇÒ¶ÔÓÚά³ÖÉñ¾­Ôª¹¦ÄÜÖÁ¹ØÖØÒª¡£Í»´¥¿ÉËÜÐÔÊÇÉñ¾­Ôª»Ø·¶Ô¸÷Öֱ仯ÈçѧϰºÍ¼ÇÒä¡¢»·¾³Ó°ÏìºÍÄÔËðÉ˵ȷ¢Éú½á¹¹ºÍ¹¦ÄÜÊÊÓ¦ÐÔ¡£Í»´¥¿ÉËÜÐÔ¿ÉÒÔÔöÇ¿»ò½µµÍÍ»´¥´«µÝµÄÇ¿¶È£¬µ¼ÖÂÍ»´¥´«µÝÎȶ¨·Å´óµÄ¿ÉËÜÐÔ³ÆΪ³¤ÆÚÔöÇ¿£¨long-term potentiation, LTP£©£¬µ¼ÖÂÍ»´¥Ç¿¶È½µµÍµÄ³ÆΪ³¤ÆÚÒÖÖÆ£¨long-term depression, LTD£©[35]¡£ÖÐÊàÉñ¾­ÏµÍ³ÖеÄÐí¶àÍ»´¥ÓɹȰ±ËáÊÜÌå×é³É£¬ÕâЩͻ´¥ÊÜÌåÓ볤ÆÚÔöÇ¿×÷ÓÃÏà¹Ø£¬Ö÷Òª²ÎÓëÍ»´¥¿ÉËÜÐÔµÄÐγÉ[36]¡£

¡¡¡¡Ñо¿±íÃ÷£¬º£ÂíºÍƤ²ãµÄÍ»´¥É¥Ê§¿ÉÄÜÊÇÔì³ÉADÈÏÖª¹¦ÄÜÕÏ°­µÄÖ÷ÒªÔ­Òò[37]¡£MMPsÔÚÓëѧϰÏà¹ØµÄÉñ¾­»Ø·ÐÞÊιý³ÌÖÐÆð׏ؼü×÷Ó㬲»Í¬ÀàÐ͵ÄMMPsÐÞÊÎϸ°ûÍâÍ»´¥ÖÜΧ»·¾³£¬µ¼ÖÂÍ»´¥¿ÉËÜÐԱ仯¡£¹È°±ËáÊÜÌåN-¼×»ù-D-Ì춬°±ËáÊÜÌåÊÇ¿ØÖÆÍ»´¥¿ÉËÜÐԺͼÇÒ书ÄܵÄÖ÷Òª·Ö×Ó×°Öá£GorkiewicµÈ[38]±íÃ÷MMP-9ø»îÐÔÔö¼ÓÁ˺¬ÓÐNR1ÑÇ»ùµÄN-¼×»ù-D-Ì춬°±ËáÊÜÌåµÄתÒÆ¡£MMP-9¿ÉÒÔÓÐЧµØÇиîÍ»´¥µ°°×£¬¶ø²»»áÒýÆðϸ°ûÍâ»ùÖʽṹµÄ´ó±ä»¯£¬¿ÉÒÔÐÞÊÎÖØÒªµÄÍ»´¥ÊÜÌåµÄÐÐΪ²¢¸Ä±äÍ»´¥µÄÐÎ̬¡£Òò´Ë£¬MMP-9»ý¼«²ÎÓëÍ»´¥ÖØËÜ[39]¡£MMP-9»ùÒòÇóýСÊóÔÚ»ùÓÚº£ÂíµÄѧϰºÍ¼ÇÒäÖбíÏÖ³öÐÐΪÕÏ°­£¬MMP-9»ùÒòÇóýСÊóµÄº£ÂíÇÐƬÅàÑøÎïÏÔʾLTPÊÜË𣬴ӶøË𺦼ÇÒ书ÄÜ£¬Õâ¿Éͨ¹ýÓ¦ÓÃÖØ×éMMP-9À´»Ö¸´[40]¡£´ËÍ⣬MT3-MMPºÍADµÄ·¢Õ¹ÃÜÇÐÏà¹Ø¡£Ê×ÏÈ£¬MT3-MMPÔÚСÊó´óÄÔƤ²ãÖй㷺±í´ï£¬Æ书ÄÜɥʧ»á¸ÉÈÅÓÎÀëƤÖÊÉñ¾­ÔªºÍÌåÄÚÐË·ÜÐÔÍ»´¥µÄ·¢Óý[41]¡£Æä´Î£¬ÔÚÒÀÀµº£ÂíµÄѧϰ¹ý³ÌÈçË®ÃÔ¹¬ÖУ¬MT3-MMP»îÐÔºÍmRNAµÄˮƽÔÚʵÑ鿪ʼµÄÇ°ÆÚÉý¸ß£¬Õâ¿ÉÄܱíÃ÷½Ï¸ßµÄMT3-MMPˮƽÔÚÏà¶Ô¶ÌµÄʱ¼äÄÚºÜÖØÒª£¬ÔÚ´ËÆÚ¼ä»áÓÕ·¢Í»´¥¿ÉËÜÐÔÏÖÏó[42]¡£

¡¡¡¡7 ¡¢Ð¡½áÓëÕ¹Íû

¡¡¡¡Ëæ×ÅÑо¿µÄÉîÈ룬MMPs½ö×÷Ϊ·ÇÌØÒìÐÔ½µ½âøµÄ´«Í³¹ÛµãÒѾ­¹ýʱ¡£ËüÃÇÔÚÉñ¾­ÍËÐÐÐÔ¼²²¡ÖÐͨ¹ý¶¯Ô±Óëµ×ÎïµÄµ°°×Ë®½â×÷ÓÃÒÔ¼°²úÉú¾ßÓÐÉúÎï»îÐÔÁѽâ²úÎï·¢»Ó×ÅÓÐÒæ»òÕßÓꦵÄÓ°Ïì¡£ÈçÔÚADÖУ¬ËüÃÇ¿ÉÒÔͨ¹ý´Ù½øAβµÄ½µ½âºÍ¿ÉÈÜÐÔAβµÄ²úÉú¡¢µ÷½ÚÍ»´¥¿ÉËÜÐԵȷ¢»ÓÉñ¾­±£»¤×÷Óá£Í¬Ê±Ò²¿ÉÒÔͨ¹ýÆÆ»µÑªÄÔÆÁÕϺÍѪҺ-ÄÔ¼¹ÒºÆÁÕÏ¡¢´Ù½øÉñ¾­Ñ×Ö¢¡¢´Ù½øTauµ°°×¹Ñ¾ÛÌåµÄÐγɵÈËðÉËÉñ¾­Ôª¡£Òò´Ë£¬ÔÚδÀ´ÎÒÃÇ¿ÉÒÔͨ¹ý¸ßͨÁ¿µ°°×ÖÊ×éѧ¼¼Êõ¾«×¼¼ø¶¨³öËüÃǵÄ×÷Óõ×Î¶ÔËùÉæ¼°µÄ²¡ÀíÉúÀí»úÖÆÓÐ͸³¹µÄÁ˽⣬ÒÔ´Ù½øабêµÄʶ±ðºÍ´´ÐÂÖÎÁƲßÂÔµÄÓ¦Óá£

¡¡¡¡²Î¿¼ÎÄÏ×

¡¡¡¡[1] Lane CA, Hardy J, Schott JM. Alzheimer's disease [J]. Eur J Neurol, 2018, 25(1): 59-70.
¡¡¡¡[2] Tublin JM, Adelstein JM, Del Monte F, et al. Getting to the heart of alzheimer disease [J]. Circ Res, 2019, 124(1): 142-149.
¡¡¡¡[3] Beroun A, Mitra S, Michaluk P, et al. MMPs in learning and memory and neuropsychiatric disorders [J]. Cell Mol Life Sci, 2019, 76(16): 3207-3228.
¡¡¡¡[4] Rempe RG, Hartz AMS, Bauer B. Matrix metalloproteinases in the brain and blood-brain barrier: Versatile breakers and makers [J]. J Cereb Blood Flow Metab, 2016, 36(9): 1481-1507.
¡¡¡¡[5] Rivera S, García-González L, Khrestchatisky M, et al. Metalloproteinases and their tissue inhibitors in Alzheimer's disease and other neurodegenerative disorders [J]. Cell Mol Life Sci, 2019, 76(16): 3167-3191.
¡¡¡¡[6] Wang J, Gu BJ, Masters CL, et al. A systemic view of Alzheimer disease - insights from amyloid-β metabolism beyond the brain [J]. Nat Rev Neurol, 2017, 13(10): 612-623.
¡¡¡¡[7] Tarasoff-Conway JM, Carare RO, Osorio RS, et al. Clearance systems in the brain-implications for Alzheimer disease [J]. Nat Rev Neurol, 2015, 11(8): 457-470.
¡¡¡¡[8] Liao MC, Van nostrand WE. Degradation of soluble and fibrillar amyloid beta-protein by matrix metalloproteinase (MT1-MMP) in vitro [J]. Biochemistry, 2010, 49(6): 1127-1136.
¡¡¡¡[9] Paumier JM, Py NA, García-González L, et al. Proamyloidogenic effects of membrane type 1 matrix metalloproteinase involve MMP-2 and BACE-1 activities, and the modulation of APP trafficking [J]. FASEB J, 2019, 33(2): 2910-2927.
¡¡¡¡[10] Porter KN, Sarkar SN, Dakhlallah DA, et al. Medroxyprogesterone acetate impairs amyloid beta degradation in a matrix metalloproteinase-9 dependent manner [J]. Front Aging Neurosci, 2020, 12: 92.
¡¡¡¡[11] Hernandez-Guillamon M, Mawhirt S, Blais S, et al. Sequential amyloid-β degradation by the matrix metalloproteases MMP-2 and MMP-9 [J]. J Biol Chem, 2015, 290(24): 15078-15091.
¡¡¡¡[12] White AR, Du T, Laughton KM, et al. Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity [J]. J Biol Chem, 2006, 281(26): 17670-17680.
¡¡¡¡[13] Taniguchi M, Matsuura K, Nakamura R, et al. MMP-7 cleaves amyloid β fragment peptides and copper ion inhibits the degradation [J]. Biometals, 2017, 30(5): 797-807.
¡¡¡¡[14] Cockerill I, Oliver JA, Xu H, et al. Blood-brain barrier integrity and clearance of amyloid-β from the BBB [J]. Adv Exp Med Biol, 2018, 1097: 261-278.
¡¡¡¡[15] Storck SE, Pietrzik CU. Endothelial LRP1 - a potential target for the treatment of Alzheimer's disease : theme: drug discovery, development and delivery in Alzheimer's disease guest editor: davide brambilla [J]. Pharm Res, 2017, 34(12): 2637-2651.
¡¡¡¡[16] Sweeney MD, Zhao Z, Montagne A, et al. Blood-brain barrier: from physiology to disease and back [J]. Physiol Rev, 2019, 99(1): 21-78.
¡¡¡¡[17] Montagne A, Barnes SR, Sweeney MD, et al. Blood-brain barrier breakdown in the aging human hippocampus [J]. Neuron, 2015, 85(2): 296-302.
¡¡¡¡[18] Spampinato SF, Merlo S, Sano Y, et al. Astrocytes contribute to Aβ-induced blood-brain barrier damage through activation of endothelial MMP9 [J]. J Neurochem, 2017, 142(3): 464-477.
¡¡¡¡[19] Zhou C, Li MY, Liu ZX, et al. Effects of moxibustion on the structure and function of blood brain barrier in Alzheimer's disease model rats [J]. Zhongguo Ying Yong Sheng Li Xue Za Zhi, 2019, 35(5): 443-446.
¡¡¡¡[20] Zhang Y, Fan F, Zeng G, et al. Temporal analysis of blood-brain barrier disruption and cerebrospinal fluid matrix metalloproteinases in rhesus monkeys subjected to transient ischemic stroke [J]. J Cereb Blood Flow Metab, 2017, 37(8): 2963-2974.
¡¡¡¡[21] Brkic M, Balusu S, Van Wonterghem E, et al. Amyloid β oligomers disrupt blood-CSF barrier integrity by activating matrix metalloproteinases [J]. J Neurosci, 2015, 35(37): 12766-12778.
¡¡¡¡[22] Sarlus H, Heneka MT. Microglia in Alzheimer's disease [J]. J Clin Invest, 2017, 127(9): 3240-3249.
¡¡¡¡[23] Sawikr Y, Yarla NS, Peluso I, et al. Neuroinflammation in Alzheimer's disease: The preventive and therapeutic potential of polyphenolic nutraceuticals [J]. Adv Protein Chem Struct Biol, 2017, 108: 33-57.
¡¡¡¡[24] Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases [J]. J Pathol, 2003, 200(4): 448-464.
¡¡¡¡[25] Woo MS, Park JS, Choi IY, et al. Inhibition of MMP-3 or -9 suppresses lipopolysaccharide-induced expression of proinflammatory cytokines and iNOS in microglia [J]. J Neurochem, 2008, 106(2): 770-780.
¡¡¡¡[26] Kim YS, Choi DH, Block ML, et al. A pivotal role of matrix metalloproteinase-3 activity in dopaminergic neuronal degeneration via microglial activation [J]. FASEB J, 2007, 21(1): 179-187.
¡¡¡¡[27] Ransohoff RM, Brown MA. Innate immunity in the central nervous system [J]. J Clin Invest, 2012, 122(4): 1164-1171.
¡¡¡¡[28] S?rbulescu RF, Ilie? I, Zupanc GK. Matrix metalloproteinase-2 and -9 in the cerebellum of teleost fish: Functional implications for adult neurogenesis [J]. Mol Cell Neurosci, 2015, 68: 9-23.
¡¡¡¡[29] Gandhi NS, Kukic P, Lippens G, et al. Molecular dynamics simulation of tau peptides for the investigation of conformational changes induced by specific phosphorylation patterns [J]. Methods Mol Biol, 2017, 1523: 33-59.
¡¡¡¡[30] Nanavaty N, Lin L, Hinckley SH, et al. Detection and quantification methods for fibrillar products of in vitro tau aggregation assays [J]. Methods Mol Biol, 2017, 1523:101-111.
¡¡¡¡[31] Wischik CM, Staff RT, Wischik DJ, et al. Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease [J]. J Alzheimers Dis, 2015, 44(2): 705-720.
¡¡¡¡[32] Maeda S, Sahara N, Saito Y, et al. Increased levels of granular tau oligomers: an early sign of brain aging and Alzheimer's disease [J]. Neurosci Res, 2006, 54(3): 197-201.
¡¡¡¡[33] Cárdenas-Aguayo Mdel C, Gómez-Virgilio L, Derosa S, et al. The role of tau oligomers in the onset of Alzheimer's disease neuropathology [J]. ACS Chem Neurosci, 2014, 5(12): 1178-1191.
¡¡¡¡[34] Nübling G, Levin J, Bader B, et al. Limited cleavage of tau with matrix-metalloproteinase MMP-9, but not MMP-3, enhances tau oligomer formation [J]. Exp Neurol, 2012, 237(2): 470-476.
¡¡¡¡[35] Citri A, Malenka RC. Synaptic plasticity: multiple forms, functions, and mechanisms [J]. Neuropsychopharmacology, 2008, 33(1): 18-41.
¡¡¡¡[36] Skaper SD, Facci L, Zusso M, et al. Synaptic plasticity, dementia and Alzheimer disease [J]. CNS Neurol Disord Drug Targets, 2017, 16(3): 220-233.
¡¡¡¡[37] Rai S, Kamat PK, Nath C, et al. A study on neuroinflammation and NMDA receptor function in STZ (ICV) induced memory impaired rats [J]. J Neuroimmunol, 2013, 254(1-2): 1-9.
¡¡¡¡[38] Gorkiewicz T, Szczuraszek K, Wyrembek P, et al. Matrix metalloproteinase-9 reversibly affects the time course of NMDA-induced currents in cultured rat hippocampal neurons [J]. Hippocampus, 2010, 20(10): 1105-1108.
¡¡¡¡[39] Stawarski M, Rutkowska-Wlodarczyk I, Zeug A, et al. Genetically encoded FRET-based biosensor for imaging MMP-9 activity [J]. Biomaterials, 2014, 35(5): 1402-1410.
¡¡¡¡[40] Nagy V, Bozdagi O, Matynia A, et al. Matrix metalloproteinase-9 is required for hippocampal late-phase long-term potentiation and memory [J]. J Neurosci, 2006, 26(7): 1923-1934.
¡¡¡¡[41] Sanz RL, Ferraro GB, Kacervosky J, et al. MT3-MMP promotes excitatory synapse formation by promoting Nogo-66 receptor ectodomain shedding [J]. J Neurosci, 2018, 38(3): 518-529.
¡¡¡¡[42] Meighan SE, Meighan PC, Choudhury P, et al. Effects of extracellular matrix-degrading proteases matrix metalloproteinases 3 and 9 on spatial learning and synaptic plasticity [J]. J Neurochem, 2006, 96(5): 1227-1241.

×÷Õßµ¥Î»£ººÓÄÏÖÐÒ½Ò©´óѧ»ù´¡Ò½Ñ§Ôº ºÓÄÏÖÐÒ½Ò©´óѧÖÐÒ½Ò©¿ÆѧԺ
Ô­Îijö´¦£ºÑîÈ÷,ÕÅÕñÇ¿,ËξüÓª,¸ß°®Éç.»ùÖʽðÊôµ°°×øÔÚ°¢¶û´Äº£Ä¬²¡·¢²¡»úÖÆÖеÄ×÷ÓÃ[J/OL].Öйú±È½ÏҽѧÔÓÖ¾:1-6[2021-03-01].http://h-s.kns.cnki.net.forest.naihes.cn/kcms/detail/11.4822.R.20210225.1811.021.html.
Ïà¹Ø±êÇ©£º
  • ±¨¾¯Æ½Ì¨
  • ÍøÂç¼à²ì
  • ±¸°¸ÐÅÏ¢
  • ¾Ù±¨ÖÐÐÄ
  • ´«²¥ÎÄÃ÷
  • ³ÏÐÅÍøÕ¾